News

Patients with spinal muscular atrophy (SMA) types 2 and 3 are at risk of malnutrition, altered metabolic rates, and changes in body composition, a study reports. The study, “Comprehensive nutritional and metabolic assessment in patients with spinal muscular atrophy: Opportunity for an individualized approach,” appeared in…

We have collected resource links to help you quickly find the information you need, related to SMA specific Nurse/Nurse Practitioner Resources.

We have collected resource links to help you quickly find the information you need, related to SMA specific Orthopedics Resources.

Over the next 20 years, the number of Americans with spinal muscular atrophy (SMA) will rise from 10,000 to nearly 15,000 — and 8,000 of those living with SMA today will still be alive come 2038, predicts Kenneth Hobby, president of Cure SMA. The Chicago-based nonprofit has been working…

A new way of restoring potentially adequate levels of survival motor neuron (SMN) — the protein missing in spinal muscular atrophy (SMA) — uses small molecules that target the structure of an intermediate player in this protein’s production. The study on this approach, “Targeting RNA structure in SMN2…

Neurological health depends as much on signals sent by the body’s leg muscles to the brain as it does on those sent from the brain to the muscles, according to a recent study. These results offer new clues as to why patients with neurological diseases such as spinal muscular atrophy (SMA)…

Exicure’s gene c prolongs survival, increases the amount of SMN proteins, and shows limited toxicity in a mouse model of the disease, study data show. The investigational compound is a spherical nucleic acid (SNA) formulation of nusinersen, the active substance in Spinraza, made by Biogen and approved to treat…

Targeted therapies or dietary supplements that work to improve the metabolism of certain molecules in muscle cells may slow the progression of spinal muscular atrophy (SMA), results of an early study in mice show. The study, “Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes…

A program offered through a partnership between Invitae Corporation and Biogen offers free genetic testing to infants, children and others with clinically diagnosed spinal muscular atrophy or suspected of having the disease. The program, SMA Identified, aims to increase access to genetic testing for the SMA community, so that diagnosis can be confirmed early in the disease process and patients or their caregivers/parents discuss treatment opinions with healthcare professionals. SMA Identified works by detecting SMN1 whole-gene deletions and sequence variants and by quantifying SMN2 copy number. The genetic test could be used to confirm a suspected or clinical diagnosis of SMA, to determine the number of  SMN2 copies in a person with an established SMA diagnosis, to check for the disease in people with a family history of SMA, and to test first-degree relatives of people diagnosed with SMA via genetic testing. The program is open to anyone eligible for it in the United States and Puerto Rico, upon a request made by a qualified healthcare provider. Biogen, which produces Spinraza, the first and only approved treatment for SMA — and approved for all types — is providing financial support to SMA Identified, but will not receive any information on SMA patients identified through it, the release states. In February, the Advisory Committee on Heritable Disorders in Newborns and Children recommended newborn screening for SMA in every state. Arthur Burghes, a professor at Ohio State University, also called for newborn screening for SMA in a keynote lecture at the start of this year's International Scientific Congress on Spinal Muscular Atrophy in Kraków, Poland.